Health

Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annualDrugs to Watc...

2025-01-08 16:12 1433

Babies Bliss Singapore: Fertility and Maternity Wellness Services to Support Couples on Their Conception Journey

Empowering Couples to Optimize Their Health and Embrace a Holistic Path to Parenthood SINGAPORE, Jan. 8, 2025 /PRNewswire/ -- For couples facing the emotional and physical challenges of trying to conceive—whether they've experienced failed IVF cycles, multiple miscarriages, or are considering IV...

2025-01-08 15:22 1635

GenScript Biotech Becomes a PSCI Supplier Partner, Advancing a Sustainable Pharmaceutical Supply Chain

PISCATAWAY, N.J., Jan. 7, 2025 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences research and manufacturing services, has officially joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner. This milestone marks significant progress in GenScript...

2025-01-08 11:30 1163

1st Official MINISH Seminar in Tokyo. 100 Dentists Expected to Attend

SEOUL, South Korea, Jan. 8, 2025 /PRNewswire/ -- MINISH Technology Inc has announced its first clinical case seminar inJapan. The seminar will take place at the Shinagawa Season Terrace inTokyo at 1 PM on the 16th of February. The event is expected to welcome 100 dentists from acrossJapan, all re...

2025-01-08 07:10 1433

Renue by Science Launches Innovative Liposomal NAD+ Skincare Line, Renue Blue, Emphasizing Skin Wellness and Longevity

JACKSONVILLE, Fla., Jan. 8, 2025 /PRNewswire/ -- Renue by Science™, a global leader in NAD+ precursor supplements, is excited to announce the official launch of its highly anticipated skincare range, Renue Blue™. With a focus on skin longevity and holistic wellness, this revolutionary line featur...

2025-01-08 03:08 1199

MedicosBiotech Wins CES 2025 Innovation Award in Digital Health

SEOUL, South Korea, Jan. 7, 2025 /PRNewswire/ -- MedicosBiotech proudly announces its recognition at CES 2025, the world's premier technology event, as a recipient of the prestigious CES Innovation Award in the Digital Health category. This award honors excellence in innovation, technology, and d...

2025-01-08 01:00 1510

Wearable Robotics Leading Company WIRobotics to Introduce Ultra-Lightweight Walking Assistance Wearable Robot WIM to the U.S. Market

Revolutionizing Personal Mobility and Healthcare for All Ages Proven Innovation Backed by CES Awards and Success in the Korean Market YONGIN, South Korea, Jan. 7, 2025 /PRNewswire/ --  WIRobotics, a pioneering leader in wearable robotics co-led by Yeon-baek Lee and Yong-jae Kim, is set to launch...

2025-01-08 01:00 1426

Insilico Received Positive Topline Results from Two Phase 1 Trials of ISM5411, New Drug Designed Using Generative AI for the Treatment of Inflammatory Bowel Disease

* Two separate Phase I studies conducted in Australia and in China indicate that ISM5411 was generally safe and well tolerated in all dose groups, demonstrating a favorable PK profile in validating gut-restrictive properties. * Supported by Insilico's commercially-available generative AI platf...

2025-01-07 22:00 902

iWOW Unveils Age-Tech Innovations at CES 2025, Expanding Portfolio of IoT Solutions for Ageing-In-Place

SINGAPORE, Jan. 7, 2025 /PRNewswire/ -- SGX-listed iWOW Technology Limited (" iWOW" or the "Company"), a Singapore-based provider of IoT solutions, is thrilled to introduce two groundbreaking Age-Tech products at CES 2025 – theBOP Monitor and BOP Presence – which complement the existing BOP Button...

2025-01-07 21:18 6141

GORTEC Announces New Trial Success for Head and Neck Cancer Treatment

TOURS, France, Jan. 7, 2025 /PRNewswire/ -- GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, as a post-operative treatment component for resected pa...

2025-01-07 21:00 1143

Alebund Pharmaceutical announced the 1st closing of RMB 550 million in Series C financing

SHANGHAI and YANGZHOU, China, Jan. 7, 2025 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for renal diseases and related chronic conditions, announced the closing ...

2025-01-07 21:00 1230

Verismo Therapeutics Announces Strategic Partnership with IFLI to Support SynKIR™-310 Development in Follicular Lymphoma

* Verismo will receive up to $4.05 million USD in investments from the Institute for Follicular Lymphoma Innovation (IFLI). * The partnership with IFLI will accelerate the clinical development of SynKIR™-310 in Follicular Lymphoma (FL) by leveraging IFLI's expertise and network, expanding cli...

2025-01-07 21:00 1129

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

TAMPA, Fla., Jan. 7, 2025 /PRNewswire/ -- Concept Medical Inc. , a global leader in innovative drug-delivery technology, proudly reports positive outcomes from theSIRONA (Head-to-Head Comparison ofSIROlimus versus Paclitaxel Drug-Eluting BallooN Angioplasty in th...

2025-01-07 20:14 1505

Eyebright Medical Receives NMPA Class III Certificate for its Phakic Intraocular Lens

HONG KONG, Jan. 7, 2025 /PRNewswire/ -- Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together with its subsidiaries collectively known as the "Group") is proud to announce that our Phakic intraocular lens, "Loong Crystal PR", has rec...

2025-01-07 20:07 1653

U.S. FDA Granted Priority Review to Dizal's Sunvozertinib New Drug Application

* If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with EGFR exon20ins * Sunvozertinib's NDA was submitted based on the multinational pivotal WU-KONG1 Part B study, the results of which were presented...

2025-01-07 18:00 1201

Weimai bags RMB200m in Series D funding to enhance tech-enabled, continuous healthcare services

The latest funding round will fuel Weimai's efforts to expand its full-cycle healthcare solutions, leveraging AI and digital tools to provide comprehensive care acrossChina HANGZHOU, China, Jan. 7, 2025 /PRNewswire/ -- Weimai, a leading provider of one-stop digital healthcare solutions inChina, ...

2025-01-07 16:19 1564

UnionPay International Partners with P.MED and StudyPENANG to Enhance Penang's Healthcare and Education Sectors, Strengthening its Position as the Preferred Payment Solution for International Tourists and Students

GEORGE TOWN, Malaysia, Jan. 7, 2025 /PRNewswire/ -- UnionPay International, a global leader in payment solutions, is proud to announce a landmark partnership with the Penang Centre for Medical Tourism (P.MED) and StudyPENANG. This strategic collaboration reinforces UnionPay International's commit...

2025-01-07 15:43 3667

Akeso to Share Global Strategy for New Drug Development at the 43rd J.P. Morgan Healthcare Conference

HONG KONG and SAN FRANCISCO, Jan. 6, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference, taking place onJanuary 13, 2025, in San Francisco, California. The company's founder, ...

2025-01-07 11:18 1257

NUS researchers boost chemotherapy uptake in breast cancer treatment with localised magnetic fields

A recent study explained the mechanisms by which pulsed electromagnetic field therapy enhances doxorubicin uptake, paving the way for precision-driven cancer therapies with fewer side effects SINGAPORE, Jan. 6, 2025 /PRNewswire/ -- Researchers at the National University of Singapore (NUS) have d...

2025-01-07 09:33 1127

The Registrational Clinical Data of Glecirasib was Published in Nature Medicine

BEIJING, SHANGHAI and BOSTON, Jan. 6, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced today that the data from a registrational clinical trial of its independently developed KRAS G12C inhibitor glecirasib has been publishe...

2025-01-07 08:30 1057
1 ... 78910111213 ... 873